Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.

<h4>Background</h4>Changes in renal function in chronic hepatitis C (CHC) patients receiving direct-acting antivirals (DAAs) are controversial. The evolution of neutrophil gelatinase-associated lipocalin (NGAL) in these patients remains unclear.<h4>Methods</h4>A total of 232...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yen-Chun Chen, Chen-Hao Li, Ping-Hung Ko, Chi-Che Lee, Ru-Jiang Syu, Chih-Wei Tseng, Kuo-Chih Tseng
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3357f1c91c3e4085849cc3ef03ae16cb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3357f1c91c3e4085849cc3ef03ae16cb
record_format	dspace
spelling	oai:doaj.org-article:3357f1c91c3e4085849cc3ef03ae16cb2021-12-02T20:19:30ZNeutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.1932-620310.1371/journal.pone.0256505https://doaj.org/article/3357f1c91c3e4085849cc3ef03ae16cb2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0256505https://doaj.org/toc/1932-6203<h4>Background</h4>Changes in renal function in chronic hepatitis C (CHC) patients receiving direct-acting antivirals (DAAs) are controversial. The evolution of neutrophil gelatinase-associated lipocalin (NGAL) in these patients remains unclear.<h4>Methods</h4>A total of 232 CHC patients receiving DAA at Dalin Tzu Chi Hospital from May 2016 to February 2019, were enrolled in this retrospective study. Grade 2/3 renal function deterioration, defined as a decrease in eGFR between 10% and 50% from baseline (BL) to 12 weeks after the end of treatment (P12), was investigated for its association with BL characteristics. The changes in renal function and NGAL levels were also analyzed at the SOF-base or nonSOF-base DAA.<h4>Results</h4>Sixty-two patients (26.7%) had grade 2/3 renal function deterioration at P12 after DAA therapy. Univariate analysis showed that it was associated with age (P = 0.038). Multivariate analysis indicated that age (OR = 1.033, 95% CI: 1.004-1.064, P = 0.027), sex (male; OR = 2.039, 95% CI: 1.093-3.804, P = 0.025), ACEI/ARB use (OR = 2.493, 95% CI: 1.016-6.119, P = 0.046), and BL NGAL (OR = 1.033, 95% CI: 1.001-1.067, P = 0.046) positively correlated with grade 2/3 renal function deterioration. Furthermore, eGFR was decreased (P = 0.009) and NGAL was increased (P = 0.004) from BL to P12 in CHC patients receiving SOF-based DAA.<h4>Conclusions</h4>Of the CHC patients receiving DAA therapy, 26.7% had grade 2/3 renal function deterioration at P12, and it was associated with older age, gender being male, ACEI/ARB use, and higher BL NGAL levels. In addition, NGAL might be a biomarker of nephrotoxicity at P12 in patients receiving SOF-based DAA.Yen-Chun ChenChen-Hao LiPing-Hung KoChi-Che LeeRu-Jiang SyuChih-Wei TsengKuo-Chih TsengPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 8, p e0256505 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yen-Chun Chen Chen-Hao Li Ping-Hung Ko Chi-Che Lee Ru-Jiang Syu Chih-Wei Tseng Kuo-Chih Tseng Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
description	<h4>Background</h4>Changes in renal function in chronic hepatitis C (CHC) patients receiving direct-acting antivirals (DAAs) are controversial. The evolution of neutrophil gelatinase-associated lipocalin (NGAL) in these patients remains unclear.<h4>Methods</h4>A total of 232 CHC patients receiving DAA at Dalin Tzu Chi Hospital from May 2016 to February 2019, were enrolled in this retrospective study. Grade 2/3 renal function deterioration, defined as a decrease in eGFR between 10% and 50% from baseline (BL) to 12 weeks after the end of treatment (P12), was investigated for its association with BL characteristics. The changes in renal function and NGAL levels were also analyzed at the SOF-base or nonSOF-base DAA.<h4>Results</h4>Sixty-two patients (26.7%) had grade 2/3 renal function deterioration at P12 after DAA therapy. Univariate analysis showed that it was associated with age (P = 0.038). Multivariate analysis indicated that age (OR = 1.033, 95% CI: 1.004-1.064, P = 0.027), sex (male; OR = 2.039, 95% CI: 1.093-3.804, P = 0.025), ACEI/ARB use (OR = 2.493, 95% CI: 1.016-6.119, P = 0.046), and BL NGAL (OR = 1.033, 95% CI: 1.001-1.067, P = 0.046) positively correlated with grade 2/3 renal function deterioration. Furthermore, eGFR was decreased (P = 0.009) and NGAL was increased (P = 0.004) from BL to P12 in CHC patients receiving SOF-based DAA.<h4>Conclusions</h4>Of the CHC patients receiving DAA therapy, 26.7% had grade 2/3 renal function deterioration at P12, and it was associated with older age, gender being male, ACEI/ARB use, and higher BL NGAL levels. In addition, NGAL might be a biomarker of nephrotoxicity at P12 in patients receiving SOF-based DAA.
format	article
author	Yen-Chun Chen Chen-Hao Li Ping-Hung Ko Chi-Che Lee Ru-Jiang Syu Chih-Wei Tseng Kuo-Chih Tseng
author_facet	Yen-Chun Chen Chen-Hao Li Ping-Hung Ko Chi-Che Lee Ru-Jiang Syu Chih-Wei Tseng Kuo-Chih Tseng
author_sort	Yen-Chun Chen
title	Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
title_short	Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
title_full	Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
title_fullStr	Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
title_full_unstemmed	Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
title_sort	neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis c patients receiving direct-acting antivirals.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/3357f1c91c3e4085849cc3ef03ae16cb
work_keys_str_mv	AT yenchunchen neutrophilgelatinaseassociatedlipocalinpartlyreflectsthedynamicchangesofrenalfunctionamongchronichepatitiscpatientsreceivingdirectactingantivirals AT chenhaoli neutrophilgelatinaseassociatedlipocalinpartlyreflectsthedynamicchangesofrenalfunctionamongchronichepatitiscpatientsreceivingdirectactingantivirals AT pinghungko neutrophilgelatinaseassociatedlipocalinpartlyreflectsthedynamicchangesofrenalfunctionamongchronichepatitiscpatientsreceivingdirectactingantivirals AT chichelee neutrophilgelatinaseassociatedlipocalinpartlyreflectsthedynamicchangesofrenalfunctionamongchronichepatitiscpatientsreceivingdirectactingantivirals AT rujiangsyu neutrophilgelatinaseassociatedlipocalinpartlyreflectsthedynamicchangesofrenalfunctionamongchronichepatitiscpatientsreceivingdirectactingantivirals AT chihweitseng neutrophilgelatinaseassociatedlipocalinpartlyreflectsthedynamicchangesofrenalfunctionamongchronichepatitiscpatientsreceivingdirectactingantivirals AT kuochihtseng neutrophilgelatinaseassociatedlipocalinpartlyreflectsthedynamicchangesofrenalfunctionamongchronichepatitiscpatientsreceivingdirectactingantivirals
_version_	1718374157867024384

Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.

Ejemplares similares